Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy.

The use of tumor-associated antigen (TAA) mRNA for therapeutic purposes is under active investigation. To be effective, mRNA vaccines need to deliver activation stimuli in addition to TAAs to dendritic cells (DC). In this study, we evaluated whether intranodal delivery of TAA mRNA together with TriMix, a mix of mRNA encoding CD40 ligand, constitutive active Toll-like receptor 4 and CD70, results in the in situ modification and maturation of DCs, hence, priming of TAA-specific T cells. We showed selective uptake and translation of mRNA in vivo by lymph node resident CD11c(+) cells. This process was hampered by codelivery of classical maturation stimuli but not by TriMix mRNA. Importantly, TriMix mRNA induced a T-cell-attracting and stimulatory environment, including recruitment of antigen-specific CD4(+) and CD8(+) T cells and CTLs against various TAAs. In several mouse tumor models, mRNA vaccination was as efficient in CTL induction and therapy response as vaccination with mRNA-electroporated DCs. Together, our findings suggest that intranodal administration of TAA mRNA together with mRNA encoding immunomodulating molecules is a promising vaccination strategy.

[1]  B. Neyns,et al.  Dendritic cells loaded with mRNA encoding full-length tumor antigens prime CD4+ and CD8+ T cells in melanoma patients. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[2]  Ö. Türeci,et al.  FLT3 ligand enhances the cancer therapeutic potency of naked RNA vaccines. , 2011, Cancer research.

[3]  Ö. Türeci,et al.  Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation , 2011, Gene Therapy.

[4]  B. Neyns,et al.  Therapeutic Vaccination With an Autologous mRNA Electroporated Dendritic Cell Vaccine in Patients With Advanced Melanoma , 2011, Journal of immunotherapy.

[5]  Ö. Türeci,et al.  Tumor vaccination using messenger RNA: prospects of a future therapy. , 2011, Current opinion in immunology.

[6]  K. Thielemans,et al.  mRNA: delivering an antitumor message? , 2011, Immunotherapy.

[7]  Özlem Türeci,et al.  Determinants of intracellular RNA pharmacokinetics: Implications for RNA-based immunotherapeutics , 2011, RNA biology.

[8]  M. Fotin‐Mleczek,et al.  Messenger RNA-based Vaccines With Dual Activity Induce Balanced TLR-7 Dependent Adaptive Immune Responses and Provide Antitumor Activity , 2011, Journal of immunotherapy.

[9]  U. Şahin,et al.  Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. , 2010, Cancer research.

[10]  Ira Mellman,et al.  Designing vaccines based on biology of human dendritic cell subsets. , 2010, Immunity.

[11]  H. Ueno,et al.  Dendritic Cells: Are They Clinically Relevant? , 2010, Cancer journal.

[12]  K. Karwacz,et al.  HIV-1 Lentiviral Vector Immunogenicity Is Mediated by Toll-Like Receptor 3 (TLR3) and TLR7 , 2010, Journal of Virology.

[13]  K. Breckpot,et al.  Dendritic cells for active anti-cancer immunotherapy: targeting activation pathways through genetic modification. , 2009, Endocrine, metabolic & immune disorders drug targets.

[14]  B. Neyns,et al.  Single-Step Antigen Loading and Activation of Dendritic Cells by mRNA Electroporation for the Purpose of Therapeutic Vaccination in Melanoma Patients , 2009, Clinical Cancer Research.

[15]  B. Neyns,et al.  Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[16]  Maxim N. Artyomov,et al.  T cell sensing of antigen dose governs interactive behavior with dendritic cells and sets a threshold for T cell activation , 2008, Nature Immunology.

[17]  Marleen Keyaerts,et al.  Dynamic bioluminescence imaging for quantitative tumour burden assessment using IV or IP administration of d-luciferin: effect on intensity, time kinetics and repeatability of photon emission , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[18]  H. Rammensee,et al.  Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent , 2007, Gene Therapy.

[19]  B. Neyns,et al.  Current approaches in dendritic cell generation and future implications for cancer immunotherapy , 2007, Cancer Immunology, Immunotherapy.

[20]  J. Aerts,et al.  Induction of effective therapeutic antitumor immunity by direct in vivo administration of lentiviral vectors , 2006, Gene Therapy.

[21]  Houping Ni,et al.  Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. , 2005, Immunity.

[22]  F. Brasseur,et al.  Electroporation of immature and mature dendritic cells: implications for dendritic cell-based vaccines , 2005, Gene Therapy.

[23]  B. Neyns,et al.  Exploiting dendritic cells for cancer immunotherapy: genetic modification of dendritic cells , 2004, The journal of gene medicine.

[24]  M. Dullaers,et al.  Side-by-side comparison of lentivirally transduced and mRNA-electroporated dendritic cells: implications for cancer immunotherapy protocols. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[25]  M. Bevan.  Helping the CD8+ T-cell response , 2004, Nature Reviews Immunology.

[26]  E. Gilboa,et al.  Cancer immunotherapy with mRNA‐transfected dendritic cells , 2004, Immunological reviews.

[27]  F. Brasseur,et al.  Messenger RNA-Electroporated Dendritic Cells Presenting MAGE-A3 Simultaneously in HLA Class I and Class II Molecules1 , 2004, The Journal of Immunology.

[28]  D. Weissman,et al.  mRNA Is an Endogenous Ligand for Toll-like Receptor 3* , 2004, Journal of Biological Chemistry.

[29]  C. Sousa,et al.  Toll-like receptors and dendritic cells: for whom the bug tolls. , 2004 .

[30]  C. Heirman,et al.  Induction of Influenza Matrix Protein 1 and MelanA-specific T lymphocytes in vitro using mRNA-electroporated dendritic cells , 2003, Cancer Gene Therapy.

[31]  M. Dullaers,et al.  Efficient genetic modification of murine dendritic cells by electroporation with mRNA , 2002, Cancer Gene Therapy.

[32]  P. Marrack,et al.  An inverse relationship between T cell receptor affinity and antigen dose during CD4(+) T cell responses in vivo and in vitro. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[33]  K. Breckpot,et al.  Selective activation of intracellular signalling pathways in dendritic cells for cancer immunotherapy. , 2012, Anti-cancer agents in medicinal chemistry.

[34]  B. Neyns,et al.  Immunotherapy of cancer with dendritic cells loaded with tumor antigens and activated through mRNA electroporation. , 2010, Methods in molecular biology.

[35]  S. Pascolo.  Vaccination with messenger RNA (mRNA). , 2008, Handbook of experimental pharmacology.

[36]  H. Rammensee,et al.  Genetic Vaccines and Therapy , 2006 .

[37]  C. Reis e Sousa,et al.  Toll-like receptors and dendritic cells: for whom the bug tolls. , 2004, Seminars in immunology.